Journal
CANCER GENETICS
Volume 205, Issue 9, Pages 432-435Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cancergen.2012.05.005
Keywords
MT2A; prostate cancer; SNP; case-control study
Categories
Funding
- statutory fund for Department of Cytobiochemistry, University of Lodz
Ask authors/readers for more resources
Metallothionein 2A (MT2A) is the most expressed metallothionein (MT) isoform in prostate cells. A number of studies have demonstrated altered MT2A expression in various human tumors, including prostate cancer. We conducted an association study to examine whether MT2A gene polymorphisms are associated with a risk of prostate cancer. Genotyping was conducted using a polymerase chain reaction restriction fragment length polymorphism (PCR RFLP) technique. Three single nucleotide polymorphisms (SNPs), rs28366003, rs1610216, and rs10636, were genotyped in 358 prostate cancer cases and 406 population controls. One SNP in MT2A (rs28366003) showed a positive association with prostate cancer. Compared to homozygous common allele carriers, heterozygosity for the G variant (odds ratio (OR) = 2.30, 95% confidence interval (CI): 1.50-3.47, P-trend < 0.0001; the OR assuming a dominant model 2.43 (95% CI: 1.62-3.61, P-dominant = 0.001) after adjustment for age) had a significantly increased risk of prostate cancer in a Polish population. Our data suggest that the rs28366003 SNP in MT2A is associated with the risk of prostate cancer in a Polish population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available